COVID-19与低钠血症

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (12): 1843-1847.

COVID-19与低钠血症

梁思宇^1,2, 陈适^1*, 潘慧^1,3, 贾觉睿智¹, 朱惠娟¹

中国医学科学院北京协和医学院 1.北京协和医院内分泌科卫健委内分泌重点实验室; 2.八年制临床医学专业; 3.北京协和医院医务处,北京 100730

收稿日期:2021-05-12 修回日期:2021-10-09 发布日期:2021-12-03
通讯作者: *cs0083@126.com

COVID-19 and hyponatremia

LIANG Si-yu^1,2, CHEN Shi^1*, PAN Hui^1,3, JIAJUE Rui-zhi¹, ZHU Hui-juan¹

1. Department of Endocrinology, Endocrine Key Laboratory of National Health Commission, Peking Union Medical College Hospital;2. Eight-year Program of Clinical Medicine;3. Department of Medical Affairs, Peking Union Medical College Hospital,CAMS & PUMC, Beijing 100730, China

Received:2021-05-12 Revised:2021-10-09 Published:2021-12-03
Contact: *cs0083@126.com

摘要/Abstract

摘要： 新型冠状病毒疾病(COVID-19)造成了极大的公共卫生负担。目前仍缺乏针对COVID-19的特效抗病毒药物。因此,在COVID-19的诊治中,需密切监测患者各项临床指标,并及时适当纠正不良结局相关危险因素。COVID-19常合并低钠血症。低钠血症与COVID-19患者住院时间延长、重症肺炎发生率增加、重症医学科转诊率增加以及病死率增加相关。低钠血症是早期识别重症患者的重要指标。COVID-19相关低钠血症主要由于抗利尿激素不适当分泌综合征、低血容量等病因导致,如能尽早发现并及时纠正,将能改善COVID-19低钠血症相关的不良结局。

关键词: 新型冠状病毒疾病, 低钠血症, 抗利尿激素不适当分泌综合征

Abstract: The worldwide spread of coronavirus disease 2019 (COVID-19) has caused a heavy burden on the public health of all countries. As the specific antiviral treatment is not available, it is necessary to monitor various clinical indicators, and minimize the risk factors related to poor outcomes in the management of COVID-19. COVID-19 is often presented with hyponatremia which is frequently associated with prolonged hospitalization, increased rate of intensive care unit transfer, higher risk of severe pneumonia and mortality. Hyponatremia is an important index for early identification of patients with poor prognosis. COVID-19 related hyponatremia is mainly caused by inappropriate antidiuretic hormone secretion syndrome and hypovolemia. If hyponatremia can be diagnosed and corrected in time, the poor clinical outcomes related to hyponatremia can be prevented.

Key words: coronavirus disease 2019, hyponatremia, syndrome of inappropriate antidiuresis hormone

中图分类号:

R589.4

梁思宇, 陈适, 潘慧, 贾觉睿智, 朱惠娟. COVID-19与低钠血症[J]. 基础医学与临床, 2021, 41(12): 1843-1847.

LIANG Si-yu, CHEN Shi, PAN Hui, JIAJUE Rui-zhi, ZHU Hui-juan. COVID-19 and hyponatremia[J]. Basic & Clinical Medicine, 2021, 41(12): 1843-1847.

参考文献

[1]Akirov A, Diker-Cohen T, Steinmetz T, et al. Sodium levels on admission are associated with mortality risk in hospitalized patients[J]. Eur J Intern Med, 2017, 46:25-29.
[2]Al Mawed S, Pankratz VS, Chong K, et al. Low serum sodium levels at hospital admission: outcomes among 2.3 million hospitalized patients[J]. PLoS One, 2018, 13:e0194379.doi:10.1371/journal.pone.0194379.
[3]Hao J, Li Y, Zhang X, et al. The prevalence and mortality of hyponatremia is seriously underestimated in Chinese general medical patients: an observational retrospective study[J]. BMC Nephrol, 2017, 18:328.doi:10.1186/s12882-017-0744-x.
[4]Sterns RH. Disorders of plasma sodium--causes, consequences, and correction[J]. N Engl J Med, 2015, 372:55-65.
[5]Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia[J]. Am J Med, 2009, 122:857-865.
[6]Królicka AL, Kruczkowska A, Krajewska M, et al. Hyponatremia in infectious diseases-a literature review[J]. Int J Environ Res Public Health, 2020, 17:5320.doi:10.3390/ijerph17155320.
[7]Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong[J]. Ann Intern Med, 2003, 139:715-723.
[8]Wu Y, Hou B, Liu J, et al. Risk factors associated with long-term hospitalization in patients with COVID-19: a single-centered, retrospective study[J]. Front Med (Lausanne), 2020, 7:315.doi:10.3389/fmed.2020.00315.
[9]Duan J, Wang X, Chi J, et al. Correlation between the variables collected at admission and progression to severe cases during hospitalization among patients with COVID-19 in Chongqing[J]. J Med Virol, 2020, 92:2616-2622.
[10]Khan AA, Ata F, Munir W, et al. Fluid replacement versus fluid restriction in COVID-19 associated hyponatremia[J]. Cureus, 2020, 12:e9059.doi:10.7759/cureus.9059.
[11]Tee LY, Yap B, Sidhu GK, et al. Atypical presentation of COVID-19 in an older adult: lethargy and vomiting from severe hypovolemic hyponatremia[J]. Geriatr Gerontol Int, 2020, 20:839-840.
[12]Habib MB, Sardar S, Sajid J. Acute symptomatic hyponatremia in setting of SIADH as an isolated presentation of COVID-19[J]. IDCases, 2020, 21:e00859.doi:10.1016/j.idcr.2020.e00859.
[13]Tsai CC, Wang YC, Chiang TT, et al. Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan[J]. J Formos Med Assoc, 2021, 120:713-719.
[14]Berni A, Malandrino D, Parenti G, et al. Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?[J]. J Endocrinol Invest, 2020, 43:1137-1139.
[15]Ghahramani S, Tabrizi R, Lankarani KB, et al. Labora-tory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis[J]. Eur J Med Res, 2020, 25:30.doi:10.1186/s40001-020-00432-3.
[16]Levy TJ, Richardson S, Coppa K, et al. Development and validation of a survival calculator for hospitalized patients with COVID-19[J]. medRxiv, 2020.doi:10.1101/2020.04.22.20075416.
[17]Cuesta M, Thompson C. The syndrome of inappropriate antidiuresis (SIAD)[J]. Best Pract Res Clin Endocrinol Metab, 2016, 30:175-187.
[18]Esposito P, Piotti G, Bianzina S, et al. The syndrome of inappropriate antidiuresis: pathophysiology, clinical management and new therapeutic options[J]. Nephron Clin Pract, 2011, 119:c62-73.doi:10.1159/000324653.
[19]Gemcioglu E, Karabuga B, Ercan A, et al. A case of inappropriate antidiuretic hormone secretion syndrome associated with COVID-19 pneumonia[J]. Acta Endocrinol (Buchar), 2020, 16:110-111.
[20]Sheikh MM, Ahmad E, Jeelani HM, et al. COVID-19 pneumonia: an emerging cause of syndrome of inappro-priate antidiuretic hormone[J]. Cureus, 2020, 12:e8841.doi:10.7759/cureus.8841.
[21]Yousaf Z, Al-Shokri SD, Al-soub H, et al. COVID-19-associated SIADH: a clue in the times of pandemic![J]. Am J Physiol Endocrinol Metab, 2020, 318:E882-E885.
[22]Mastorakos G, Weber JS, Magiakou MA, et al. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion[J]. J Clin Endocrinol Metab, 1994, 79:934-939.
[23]Park SJ, Shin JI. Inflammation and hyponatremia: an underrecognized condition?[J]. Korean J Pediatr, 2013, 56:519-522.
[24]Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosup-pression[J]. Lancet, 2020, 395:1033-1034.
[25]De La Flor Merino JC, Mola Reyes L, Linares Gravalos T, et al. An unusual case of severe acute hyponatremia in patient with COVID-19 infection[J]. Nefrologia, 2020, 40:356-358.